ILLUMINA, INC. ILMN

Technology SIC 3826 - Laboratory Analytical Instruments Nasdaq

Last close 218.22 2026-09-04
Market cap $32.95B 2026-06-28 share count
52-week range 88.00 - 231.81

Valuation FY2025 figures against the last close

P/S7.6x
P/E40.0x
P/FCF35.4x
EV/EBITDA30.6x
Dividend yield
Diluted EPS5.45

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $4.34B$4.37B$4.50B$4.58B$4.53B$3.24B$3.54B$3.33B$2.75B$2.40B
Cost of revenue $1.47B$1.51B$1.76B$1.61B$1.37B$1.04B$1.08B$1.03B$926.0M$732.0M
Gross profit $2.87B$2.86B$2.74B$2.97B$3.15B$2.20B$2.47B$2.30B$1.83B$1.67B
R&D $967.0M$1.17B$1.35B$1.32B$1.19B$682.0M$647.0M$623.0M$546.0M$504.0M
SG&A $1.09B$1.09B$1.61B$1.30B$2.09B$941.0M$835.0M$794.0M$674.0M$584.0M
Total operating expenses $2.06B$3.69B$3.81B$7.15B$3.28B$1.62B$1.48B$1.42B$1.22B$1.08B
Operating income $807.0M-$833.0M-$1.07B-$4.18B-$123.0M$580.0M$985.0M$883.0M$606.0M$587.0M
Interest expense $101.0M$100.0M$77.0M$26.0M$61.0M$49.0M$52.0M$57.0M$37.0M$33.0M
Pre-tax income $1.09B-$1.18B-$1.12B-$4.34B$884.0M$856.0M$1.12B$894.0M$1.04B$561.0M
Income tax $236.0M$44.0M$44.0M$68.0M$122.0M$200.0M$128.0M$112.0M$365.0M$133.0M
Net income $850.0M-$1.22B-$1.16B-$4.40B$762.0M$656.0M$1.00B$826.0M$726.0M$463.0M
EPS, basic 5.47-7.69-7.34-28.005.074.486.815.634.963.09
EPS, diluted 5.45-7.69-7.34-28.005.044.456.745.564.923.07
Shares, diluted (wtd. avg.) $156.0M$159.0M$158.0M$157.0M$151.0M$148.0M$149.0M$149.0M$148.0M$148.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $1.42B$1.13B$1.05B$2.01B$1.23B$1.81B$2.04B$1.14B$1.23B$735.0M
Short-term investments $215.0M$93.0M$6.0M$26.0M$107.0M$1.66B$1.37B$2.37B$920.0M$824.0M
Receivables $854.0M$735.0M$734.0M$671.0M$648.0M$487.0M$573.0M$514.0M$411.0M$381.0M
Inventory $564.0M$547.0M$587.0M$568.0M$431.0M$372.0M$359.0M$386.0M$333.0M$300.0M
Total current assets $3.29B$2.75B$2.61B$3.56B$2.71B$4.48B$4.45B$4.49B$2.98B$2.32B
Property, plant and equipment $759.0M$815.0M$1.01B$1.09B$1.02B$922.0M$889.0M$1.07B$931.0M$713.0M
Goodwill $1.11B$1.11B$2.54B$3.24B$7.11B$897.0M$897.0M$831.0M$771.0M$776.0M
Other intangibles $210.0M$295.0M$2.99B$3.29B$3.25B$142.0M$145.0M$185.0M$175.0M$243.0M
Total assets $6.64B$6.30B$10.11B$12.25B$15.22B$7.58B$7.32B$6.96B$5.26B$4.28B
Accounts payable $240.0M$221.0M$245.0M$293.0M$332.0M$192.0M$149.0M$184.0M$160.0M$138.0M
Short-term debt $511.0M$0$1.11B$10.0M$2.0M
Total current liabilities $1.58B$1.55B$1.57B$2.77B$1.09B$1.24B$665.0M$1.80B$746.0M$705.0M
Long-term debt $673.0M$1.14B$890.0M$1.18B$1.06B
Retained earnings -$392.0M-$1.24B-$19.0M$1.14B$5.49B$4.72B$4.07B$3.08B$2.26B$1.49B
Total equity $2.72B$2.37B$5.75B$6.60B$10.74B$4.69B$4.61B$3.85B$2.75B$2.27B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $1.08B$837.0M$478.0M$392.0M$545.0M$1.08B$1.05B$1.14B$875.0M$779.0M
Depreciation and amortisation $270.0M$354.0M$432.0M$394.0M$251.0M$187.0M$188.0M$179.0M$156.0M$141.0M
Stock-based compensation $275.0M$370.0M$380.0M$366.0M$754.0M$194.0M$194.0M$193.0M$164.0M$129.0M
Capital expenditure $148.0M$128.0M$195.0M$286.0M$208.0M$189.0M$209.0M$296.0M$310.0M$260.0M
Investing cash flow -$55.0M-$178.0M-$231.0M-$591.0M-$1.07B-$554.0M$745.0M-$1.81B-$214.0M-$515.0M
Financing cash flow -$744.0M-$570.0M-$1.21B$1.00B-$51.0M-$766.0M-$897.0M$594.0M-$176.0M-$296.0M
Buybacks $742.0M$116.0M$0$0$0$736.0M$324.0M$201.0M$251.0M$249.0M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-149669.

Others in SIC 3826

TickerCompanyMarket capP/ERevenue growth
A AGILENT TECHNOLOGIES, INC. $42.53B 33.0x 6.7%
WAT WATERS CORP /DE/ $40.22B 38.0x 7.0%
MTD METTLER TOLEDO INTERNATIONAL INC/ $26.95B 32.0x 4.0%
RVTY REVVITY, INC. $14.53B 62.9x 3.7%
BIO BIO-RAD LABORATORIES, INC. $10.33B 13.9x 0.7%
AVTR Avantor, Inc. $10.22B -3.4%
BRKR BRUKER CORP $8.88B 2.1%
TXG 10x Genomics, Inc. $8.14B 5.2%